Merck trades at an attractive 12.5x forward PE with 4 consecutive earnings beats, strong momentum (EMA stack aligned), and a 2.94% dividend yield. The $50B+ acquisition strategy signals management's urgency to build post-Keytruda revenue streams ahead of the 2028 patent cliff. Recent anti-TL1A Phase 2 success in UC opens a new immunology franchise. Risk-reward favors longs at current levels, but the Keytruda cliff and elevated PEG (5.37) temper conviction.
Merck & Co. is a global pharmaceutical leader with dominant positions in oncology, vaccines, and animal health. The crown jewel is Keytruda (pembrolizumab), the world's best-selling drug at ~$25B annual revenue, used across 30+ tumor types.
Beyond oncology, Merck's Gardasil HPV vaccine franchise and Vaxneuvance pneumonia vaccine provide recurring revenue. The Animal Health segment (Bravecto) adds diversification. Facing a 2028 Keytruda patent cliff, Merck has launched a $50B+ acquisition spree — including Spring Bioscience, EyeBio, and CN201 — plus internal pipeline assets like MK-1084 (oral PD-1), MK-5684 (prostate cancer), and a recently successful anti-TL1A antibody for immunology.
| Segment | Revenue | % Total | Description |
|---|---|---|---|
| Oncology (Keytruda) | ~50% | 50% | Keytruda (pembrolizumab) across 30+ tumor types — world's best-selling drug |
| Vaccines | ~20% | 20% | Gardasil HPV, Vaxneuvance pneumonia, other preventive vaccines |
| Hospital / Specialty | ~15% | 15% | Bridion, Prevymis, Welireg and other specialty therapeutics |
| Animal Health | ~15% | 15% | Bravecto, livestock and companion animal products |
| Metric | Value | Signal |
|---|---|---|
| Market Cap | $295.4B | Mega-cap |
| Trailing P/E | 33.69x | Elevated (charges) |
| Forward P/E | 12.51x | Value |
| PEG Ratio | 5.37x | Expensive |
| EV/EBITDA | 11.14x | Reasonable |
| EV/Revenue | 5.00x | In-line |
| Book Value | $18.58 | P/B 6.44x |
| Dividend Yield | 2.94% | Income |
| Beta | 0.218 | Defensive |
| Short Interest | 1.24% | Low |
| Quarter | EPS Actual | EPS Est. | Surprise | Revenue |
|---|---|---|---|---|
| Q1 2026 | $-1.28 | $-1.47 | +12.9% | One-time charges |
| Q4 2025 | $2.04 | $2.01 | +1.5% | - |
| Q3 2025 | $2.58 | $2.35 | +9.8% | - |
| Q2 2025 | $2.13 | $2.03 | +4.9% | - |
4/4 consecutive beats — Q1 2026 negative EPS reflects one-time Keytruda write-down/acquisition charges, not operational weakness — Next: July 2026 (est.)
| RSI (14) | 56.2 |
| EMA 20 | $116.98 |
| EMA 50 | $116.35 |
| EMA 200 | $106.05 |
| MACD | 0.210 |
| Signal | 0.490 |
| ATR (14) | $3.19 |
Healthy bullish structure with perfect EMA alignment: EMA20 ($116.98) > EMA50 ($116.35) > EMA200 ($106.05). RSI 56.17 — neutral with room to run. MACD 0.21 below signal 0.49 suggests momentum is consolidating, not reversing. ATR $3.19 (2.7%) provides manageable volatility. Price sits 2.2% above EMA20 — not extended. 52-week high at $125.14 is the key resistance to clear. Recovery of 56% from 52-week low ($76.66).
Strong pharma franchise with consistent earnings beats and deep value forward PE, but the Keytruda 2028 patent cliff and aggressive M&A integration create meaningful medium-term risk.
Merck is trading at 12.5x forward PE with a perfect EMA stack alignment and 4 consecutive earnings beats. The stock is recovering strongly from its $76.66 low, driven by healthcare sector rotation and pipeline catalysts. The anti-TL1A Phase 2 success and $50B strategic plan provide medium-term catalysts. The 2.94% dividend yield offers downside cushion while waiting for the $125 52-week high breakout.
This analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendation, or solicitation to buy or sell any security.
Past performance is not indicative of future results. All investments involve risk, including the possible loss of principal. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
Data sourced from DailyTickers Gateway, Yahoo Finance, SEC EDGAR, and public market data. Accuracy is not guaranteed.